A Phase I Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics of EB-203 Eye Drops in Healthy Volunteers
Latest Information Update: 24 Feb 2023
At a glance
- Drugs EB-203 (Primary)
- Indications Age-related macular degeneration
- Focus Adverse reactions
- Sponsors EyebioKorea
Most Recent Events
- 21 Feb 2023 Status changed from recruiting to completed.
- 20 Sep 2022 New trial record